Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Balsalazide + Parthenolide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Balsalazide||Carbadox||Balsalazida||Carbadox (balsalazide) is a 5-aminosalicylate (5-ASA) type drug that is FDA approved for the treatment of inflammation resulting from ulcerative colitis (FDA.gov), however, has also been demonstrated to induce apoptosis and decrease cell proliferation in cancer cells (PMID: 28108625).|
|Parthenolide||Parthenolide is derived from Tanacetum parthenium and is an inhibitor of NF-kB and IL-1, which potentially results in apoptosis by blocking the activation of NF-kB in cancer cells (PMID: 21603970, PMID: 28108625, PMID: 32742599, PMID: 32705224).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||Balsalazide + Parthenolide||Preclinical - Cell culture||Actionable||In a preclinical study, the combination of Balsalazide and Parthenolide resulted in a synergistic effect, resulting in reduced cell viability and increased apoptotic activity in colorectal cancer cells in culture (PMID: 28108625).||28108625|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|